Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm-Reference-Cited by-同舟云学术

Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm

Published:2016-03-14 Issue:4 Volume:21 Page:514-520
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Chapuy Claudia I.¹,Sahai Inderneel²,Sharma Rohit²,Zhu Andrew X.²,Kozyreva Olga N.¹

Affiliation:

1. a Dana-Farber Cancer Institute at St. Elizabeth’s Medical Center, Boston, Massachusetts, USA

2. b Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Abstract

Abstract We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encephalopathy biochemically consistent with acquired ornithine transcarbamylase deficiency. Awareness of FLHCC-associated hyperammonemic encephalopathy and a pathophysiology-based management approach can optimize patient outcome and prevent serious complications. A discussion of the management, literature review, and proposed treatment algorithm of this rare metabolic complication are presented.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2015-0267

Reference35 articles.

1. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database;Eggert;United European Gastroenterol J,2013

2. Fibrolamellar carcinoma: 2012 update;Torbenson;Scientifica (Cairo),2012

3. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study;El-Serag;Hepatology,2004

4. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma;Moreno-Luna;BMC Cancer,2005

5. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: Data from the fibrolamellar carcinoma consortium;Ang;Gastrointest Cancer Res,2013

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quo vadis ureagenesis disorders? A journey from 90 years ago into the future;Journal of Inherited Metabolic Disease;2024-06-04

2. Mitochondrial Calcium Signaling Regulates Branched-Chain Amino Acid Catabolism in Fibrolamellar Carcinoma;2024-05-28

3. Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma;Science Advances;2023-06-23

4. Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data;npj Precision Oncology;2023-03-23

5. Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias;Molecular Genetics and Metabolism;2022-06